Timely recruitment of the large numbers of healthy volunteers required for Phase I trials of most biosimilars is a key success factor in this competitive sector. A multi-site approach can help maximize the sponsor’s chance of gaining first-mover advantages such as regulatory exclusivity. The entire biosimilar development program must be kept in mind when setting up Phase I, particularly if accelerated approaches are being considered, such as launching a Phase III program based on Phase I interim analysis.